Results 11 to 20 of about 336,545 (312)

Effects of nanoparticles on the blood coagulation system (nanoparticle interface with the blood coagulation system)

, 2021
The blood coagulation system plays a critical role in maintaining the delicate thrombohemorrhagic balance in the body. Nanoparticles in the bloodstream can encounter and interact with one or more components of the coagulation system, which potentially ...
Tran, HDN, Xu, ZP, Akther, F, Ta, HT
core   +1 more source

Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X [PDF]

, 2010
Human adenoviruses from multiple species bind to coagulation factor X (FX), yet the importance of this interaction in adenovirus dissemination is unknown.
Angela C Bradshaw, Duffy, Margaret R., Andrew H. Baker, Lynda Coughlan, Coughlan Lynda, Baker Andrew H., van Rooijen, Nico, van Rooijen, N., Nicklin, Stuart A., Margaret R Duffy, Parker, A.L., Kahari, V.M., Alan L Parker, Kähäri Veli-Matti, Stuart A Nicklin, Nico van Rooijen, Andrew H Baker, Coughlan, L., Nicklin Stuart A., Coughlan, Lynda, Kahari, Veli-Matti, Duffy, M.R., Parker Alan L., Bradshaw Angela C., Parker, Alan L., Duffy Margaret R., Bradshaw, Angela C., Bradshaw, A.C., Rooijen, N. van, Veli-Matti Kähäri, Angela C. Bradshaw, Alan L. Parker, Margaret R. Duffy, Stuart A. Nicklin, Baker, Andrew H., Baker, A.H., Nicklin, S.A., van Rooijen Nico   +37 more
core   +1 more source

The Role of Cytokines in Activation of Coagulation and Fibrinolysis in Dengue Shock Syndrome [PDF]

, 2002
In a prospective clinical study of 50 patients with Dengue Shock Syndrome (DSS), we investigated the association of tumor necrosis factor- (TNF-), interleukin-1 (IL-1), IL-1 receptor antagonist (IL-1Ra), and IL-6 with activation markers of coagulation
Dolmans, Wil M.V., van der Meer, Jos W. M., Wil Dolmans, Setiati, T.E., Dolmans, W.M.V., C. Hack, Jos van der Meer, Hugo ten Cate, Hack, C. Erik, Hack, C.E., Djokomoeljanto, R.J., Cate, H. ten, Djokomoeljanto, Robert J., Cate, Hugo ten, Suharti, C., Catharina Suharti, Djokomoeljanto, Robert J., Gorp, E. van, Meer, J.W.M. van der, Dolmans, Wil M. V., Setiati, Tatty E., Meer, Jos W.M. van der, Eric van Gorp, Napel, C.H.H. ten, Gorp , Eric C.M. van, ten, Cate Hugo, Suharti, Catharina, Setiati , Tatty E., Robert Djokomoeljanto, Gorp, E.C.M. van, van Gorp, Eric C. M., Tatty Setiati   +31 more
core   +1 more source

Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It

Scientifica, 2012
Venous thromboembolism (VTE) that includes deep vein thrombosis and/or pulmonary embolism is a frequent, severe, and potentially lethal disease. After a first episode, VTE has a strong tendency to recur.
Gualtiero Palareti
doaj   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon, Roseline d’Oiron, Rainer B. Zotz, Niels Bindslev, Matteo Nicola Dario Di Minno, Giovanni Di Minno   +5 more
doaj   +1 more source

Platelet biomechanics, platelet bioenergetics, and applications to clinical practice and translational research

Platelets, 2018
The purpose of this review is to explore the relationship between platelet bioenergetics and biomechanics and how this relationship affects the clinical interpretation of platelet function devices. Recent experimental and technological advances highlight
Mitchell J. George, James Bynum, Prajeeda Nair, Andrew P. Cap, Charles E. Wade, Charles S. Cox, Brijesh S. Gill   +6 more
doaj   +1 more source

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia

Haematologica, 2015
Standard treatment for Glanzmann thrombasthenia is platelet transfusion. Recombinant activated factor VII has been shown to be successful in patients with Glanzmann thrombasthenia with platelet antibodies or who are refractory to platelet transfusions ...
Giovanni Di Minno, Rainer B Zotz, Roseline d’Oiron, Niels Bindslev, Matteo Nicola Dario Di Minno, Man-Chiu Poon   +5 more
doaj   +1 more source

COAGULATION OF THE BLOOD: [PDF]

The Lancet, 1920
n ...
openaire   +2 more sources

Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients

Hematology Reports
Background: Hospital-acquired deep vein thrombosis (DVT) is an important cause of morbidity and mortality. Objectives: The purpose of this study was to evaluate the prevalence of proximal lower limb DVT and isolated distal DVT (IDDVT) and their ...
Michelangelo Sartori, Miriam Fiocca, Mario Soldati, Laura Borgese, Elisabetta Favaretto, Benilde Cosmi   +5 more
doaj   +1 more source

The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes

TH Open, 2019
Background Standard treatment for Glanzmann thrombasthenia (GT), a severe inherited bleeding disorder, is platelet transfusion. Recombinant activated factor VII (rFVIIa) is reported to be effective in GT with platelet antibodies and/or refractoriness to ...
Rainer B. Zotz, Man-Chiu Poon, Giovanni Di Minno, Roseline D'Oiron   +3 more
doaj   +1 more source